PTC Therapeutics
pharmaceutical company
PTCT Nasdaq
ISIN US69366J2006 SEC CIK 1070081 LEI 549300UJLWOIWFDGB318
Follow PTC Therapeutics
Weekly email: filings, results
Revenue, last quarter
$357.8M
+69.6% vs same quarter last year
Net income
−$51.7M
−425.2% vs same quarter last year
EPS, diluted
−$0.62
−410% vs same quarter last year
Operating cash flow
−$25.3M
+61.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1.7B | $683M |
| FY24 | $806.8M | −$363.3M |
| FY23 | $937.8M | −$626.6M |
| FY22 | $698.8M | −$559M |
| FY21 | $538.6M | −$523.9M |
| FY20 | $380.8M | −$438.2M |
| FY19 | $307M | −$251.6M |
| FY18 | $264.7M | −$128.1M |
| FY17 | $194.4M | −$79M |
| FY16 | $82.7M | −$142.1M |
| FY15 | $36.8M | −$170.4M |
| FY14 | $25.2M | −$93.8M |
| FY13 | $34.7M | −$51.6M |
| FY12 | $33.9M | - |
| FY11 | $105.4M | $30.9M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | 50.1% | 39.5% |
| FY24 | - | −37.5% | −45% |
| FY23 | - | −46.9% | −66.8% |
| FY22 | - | −64% | −80% |
| FY21 | - | −69.5% | −97.3% |
| FY20 | - | −113.4% | −115.1% |
| FY19 | 96% | −78.6% | −82% |
| FY18 | 95.2% | −43.7% | −48.4% |
| FY17 | 97.6% | −33.1% | −40.6% |
| FY16 | 100% | −159.7% | −171.8% |
| FY15 | 100% | −454.6% | −463.6% |
| FY14 | - | −393.8% | −371.4% |
| FY13 | - | −130.8% | −148.6% |
| FY12 | - | −79% | - |
| FY11 | - | 29% | 29.3% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $702.3M |
| FY24 | −$114.2M |
| FY23 | −$186.9M |
| FY22 | −$388.7M |
| FY21 | −$279.5M |
| FY20 | −$211.9M |
| FY19 | −$112.4M |
| FY18 | −$34.7M |
| FY17 | −$13.2M |
| FY16 | −$105.3M |
| FY15 | −$127.1M |
| FY14 | −$61.9M |
| FY13 | −$47.8M |
| FY12 | −$48.1M |
| FY11 | −$20.9M |
- PTC Therapeutics
- Healthcare median
Show the numbers
| Year | PTC Therapeutics | Healthcare median |
|---|---|---|
| FY25 | 39.5% | −30.6% |
| FY24 | −45% | −47% |
| FY23 | −66.8% | −58% |
| FY22 | −80% | −80.4% |
| FY21 | −97.3% | −71.9% |
| FY20 | −115.1% | −62.2% |
| FY19 | −82% | −46.3% |
| FY18 | −48.4% | −49.6% |
| FY17 | −40.6% | −45.9% |
| FY16 | −171.8% | −36% |
| FY15 | −463.6% | −38.4% |
| FY14 | −371.4% | −35.5% |
| FY13 | −148.6% | −37.1% |
| FY12 | - | −29.1% |
| FY11 | 29.3% | −27.9% |